about
Melatonin for treating pre-eclampsiaMelatonin for preventing pre-eclampsiaPhase I pilot clinical trial of antenatal maternally administered melatonin to decrease the level of oxidative stress in human pregnancies affected by pre-eclampsia (PAMPR): study protocol.Future therapies for pre-eclampsia: beyond treading water.Embedding assessment in a simulation skills training program for medical and midwifery students: A pre- and post-intervention evaluation.Role of activin A in the pathogenesis of endothelial cell dysfunction in preeclampsia.A placenta clinic approach to the diagnosis and management of fetal growth restriction.A Randomized Double-Blinded Placebo-Controlled Intervention Trial of Melatonin for the Prevention of Preeclampsia in Moderate- and High-Risk Women: The MELPOP Trial.Phase I Pilot Clinical Trial of Antenatal Maternally Administered Melatonin to Decrease the Level of Oxidative Stress in Human Pregnancies Affected by Preeclampsia.Role of Activin A in the Pathogenesis of Endothelial Cell Dysfunction in Preeclampsia.FIGO consensus guidelines on placenta accreta spectrum disorders: Nonconservative surgical management.Update on uterine tachysystoleMirroring preeclampsia: the molecular basis of Ballantyne syndromeMelatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsiaActivin and NADPH-oxidase in preeclampsia: insights from in vitro and murine studiesNo. 381-Assisted Vaginal BirthNo 381 - Accouchement vaginal assistéNo. 383-Screening, Diagnosis, and Management of Placenta Accreta Spectrum DisordersNo 383 - Dépistage, diagnostic et prise en charge des troubles du spectre du placenta accreta
P50
Q24186076-8A59EE23-709A-4D88-B9D1-EEB82593966EQ24188340-B5FEFB92-A73C-4AE3-861D-CDE53849B852Q37190390-A4F3DA80-D5FD-4E23-B086-8224760DD1C0Q38151169-F9C36052-BAD6-4564-8E01-957CD1B7F3DEQ38705743-4D369331-36A8-4A23-A4A8-26AC4772D052Q39786567-721A7FF1-F61E-48A6-B1AB-E5E75E781708Q47775153-29C6ACF5-E2A8-4B9D-8D3E-347A5F64E876Q49351506-8D771760-32AD-4ABF-95B3-5C06D10824F9Q49351519-F367616D-3BEE-4B2F-BEDC-62B245D9C96EQ49351734-43206809-3225-4FA4-8950-CAE98EF73B1DQ50190731-40B02A80-C4C1-4552-AA62-B0098A0BDDA8Q57808558-CA6D9437-A057-420D-97AA-EBEE7374A999Q61846819-EFD08018-4C46-46D4-82DF-04A2E98C9EB3Q61846827-DE2361C2-CC3F-4D27-A602-0A2EA54EC15BQ61846899-1DA1210A-6581-4833-9F7E-ABCC5711182CQ92278060-A0816E69-4075-4FF7-A98E-0F4581476E9DQ92278063-AAC46FAE-1DF0-4DC5-9337-00612C0F0540Q92943178-2CD4C37F-25BE-45A2-AE3D-40547650E7ACQ92943184-4DB2C615-EC06-4FB2-81ED-0CB45F5281C7
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Sebastian R Hobson
@ast
Sebastian R Hobson
@en
Sebastian R Hobson
@es
Sebastian R Hobson
@nl
type
label
Sebastian R Hobson
@ast
Sebastian R Hobson
@en
Sebastian R Hobson
@es
Sebastian R Hobson
@nl
prefLabel
Sebastian R Hobson
@ast
Sebastian R Hobson
@en
Sebastian R Hobson
@es
Sebastian R Hobson
@nl
P106
P1153
19734395500
P31
P496
0000-0002-0576-8794